Exelon®
Exelon® (rivastigmine) is the third cholinesterase inhibitor launched for the treatment of mild to moderate dementia of the Alzheimer\'s type.
Clinical efficacy of Exelon® is similar to that of Aricept® and Cognex®, based on the Clinical Global Impression of Change (CGIC) scale and Alzheimer\'s Disease Assessment Scale-Cognitive Subscale score (ADAS-cog), but its tolerability is worse than that of Aricept®.
One of the advantages that Exelon® has over other cholinesterase inhibitors is the lack of drug interactions with other compounds.
Due to the fact that Exelon® has low protein-binding potential and is not metabolized by hepatic cytochrome P450 oxidative isoenzymes, its likelihood of interactions with other drugs is much lower.
Another advantage that Exelon® has over Aricept® is the availability of both capsule and oral solution formulation. Both formulations of Exelon®, however, are required to be taken twice daily with food.
Exelon® (rivastigmine) is the third cholinesterase inhibitor launched for the treatment of mild to moderate dementia of the Alzheimer\'s type.
Clinical efficacy of Exelon® is similar to that of Aricept® and Cognex®, based on the Clinical Global Impression of Change (CGIC) scale and Alzheimer\'s Disease Assessment Scale-Cognitive Subscale score (ADAS-cog), but its tolerability is worse than that of Aricept®.
One of the advantages that Exelon® has over other cholinesterase inhibitors is the lack of drug interactions with other compounds.
Due to the fact that Exelon® has low protein-binding potential and is not metabolized by hepatic cytochrome P450 oxidative isoenzymes, its likelihood of interactions with other drugs is much lower.
Another advantage that Exelon® has over Aricept® is the availability of both capsule and oral solution formulation. Both formulations of Exelon®, however, are required to be taken twice daily with food.
